NCT01425398View on ClinicalTrials.gov

A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Valvular Cardiac Surgery
Interventions
DRUG

Rosuvastatin

Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.

DRUG

Placebo

Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.

Trial Locations (1)

H3A 1A1

Royal Victoria Hospital, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT01425398 - A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery | Biotech Hunter | Biotech Hunter